Seagen's Tukysa® (tucatinib) was approved in the UK as part of a combination regimen for the treatment of adults with locally advanced or metastatic HER2-positive breast cancer.
List view / Grid view
HER2-positive breast cancer
Filter the results
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.